H.C. Wainwright Reiterates Buy Rating on Crinetics (CRNX)

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $81.00 price target on Crinetics (NASDAQ: CRNX).

The analyst commented: "As part of our "Emerging Ideas In Biopharma" call series, we recently hosted Dr. Alan Krasner, Chief Endocrinologist of Crinetics Pharmaceuticals, and Isabel Kalofonos, Chief Commercial Officer of the company. We discussed the breadth of potential of paltusotine in acromegaly, focusing on clinician feedback to the new data presented at AACE in surgically naïve patients. We also discussed the company’s pre-launch efforts and commercial landscape in acromegaly. We then spent time discussing the registrational studies of atumelnant in Congenital Adrenal Hyperplasia (CAH) and the company’s latest Phase 1 oncology candidate CRN09682. Crinetics has been one of our favorite stories for some time based on the company's differentiated capabilities in drug discovery and increasingly clinical development. The key takeaways from our discussion are summarized within. We reiterate our Buy and our price target of $81 for Crinetics."

For an analyst ratings summary and ratings history on Crinetics click here. For more ratings news on Crinetics click here.

Shares of Crinetics closed at $30.52 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform
• Texas screwworm case 'presumptive positive,' USDA tells industry members - Reuters